{"id":8131,"date":"2026-10-22T08:00:00","date_gmt":"2026-10-22T06:00:00","guid":{"rendered":"https:\/\/chemspx.com\/?p=8131"},"modified":"2026-10-13T10:28:06","modified_gmt":"2026-10-13T08:28:06","slug":"when-should-ivrt-be-used-instead-of-ivpt-in-formulation-development","status":"publish","type":"wiki_post","link":"https:\/\/chemspx.com\/nl\/wiki\/when-should-ivrt-be-used-instead-of-ivpt-in-formulation-development\/","title":{"rendered":"When should IVRT be used instead of IVPT in formulation development?"},"content":{"rendered":"<p>Use <strong>IVRT (in vitro release testing)<\/strong> when the goal is to characterize how a drug releases from its formulation matrix, particularly during early development, quality control, or comparative studies between formulations. Switch to <strong>IVPT (in vitro permeation testing)<\/strong> when you need to understand how a drug crosses a biological membrane, which is required for bioequivalence assessments and more advanced efficacy-related research. The choice depends primarily on whether membrane transport is scientifically or regulatorily relevant to your development stage. The sections below address the most common questions researchers and formulation scientists face when deciding between these two methods.<\/p>\n<h2>What is the key difference between IVRT and IVPT?<\/h2>\n<p>IVRT and IVPT differ in whether a biological or synthetic membrane is used to simulate skin permeation. In vitro release testing measures the rate at which an active substance is released from a formulation into an acceptor medium, using an inert synthetic membrane that does not impede transport. In vitro permeation testing adds a biological barrier, typically excised human or animal skin, to assess how much drug actually crosses that barrier over time.<\/p>\n<p>This distinction has significant downstream consequences for what each test can tell you. IVRT reflects formulation performance, meaning it captures how well the vehicle releases the drug independent of skin properties. IVPT reflects the combined effect of the formulation and the skin&#8217;s own transport characteristics, making it a closer model of what happens in a real biological context.<\/p>\n<p>Both methods typically use Franz diffusion cells or similar membrane diffusion systems, but the choice of membrane is what separates them conceptually and practically. IVRT uses membranes such as synthetic cellulose or silicone, while IVPT relies on excised skin tissue, which introduces biological variability but also biological relevance.<\/p>\n<h2>When is IVRT the appropriate method to use?<\/h2>\n<p>IVRT is the appropriate method when the research objective centers on formulation characterization rather than biological permeation. It is particularly well-suited for early-stage development, quality control, and comparative studies where the goal is to distinguish between formulations or detect changes in the manufacturing process.<\/p>\n<p>Specific situations where IVRT is the preferred approach include:<\/p>\n<ul>\n <li>Screening multiple formulation prototypes to identify which vehicle provides optimal drug release<\/li>\n <li>Demonstrating sameness between a reference and test semi-solid formulation for regulatory submissions<\/li>\n <li>Monitoring batch-to-batch consistency during scale-up or manufacturing changes<\/li>\n <li>Stability studies that require a reproducible, low-variability method<\/li>\n <li>Situations where biological tissue is unavailable, cost-prohibitive, or ethically restricted<\/li>\n<\/ul>\n<p>Because IVRT uses synthetic membranes, results are highly reproducible and less subject to the biological variability inherent in skin tissue. This makes it a robust tool for comparative and quality-related work, even when skin permeation data is not the scientific question being asked.<\/p>\n<h2>When does IVPT become necessary instead of IVRT?<\/h2>\n<p>IVPT becomes necessary when the research question involves how a drug interacts with and crosses biological skin. This is required in bioequivalence studies for topical formulations, where demonstrating that a test product performs comparably to a reference product at the level of membrane transport is essential.<\/p>\n<p>Regulatory agencies have increasingly recognized IVPT as a viable tool for bioequivalence assessment of complex topical products, particularly for formulations where in vivo studies are difficult to conduct or interpret. In these contexts, IVRT alone is insufficient because it does not capture the skin&#8217;s role as a selective barrier.<\/p>\n<p>IVPT is also necessary when:<\/p>\n<ol>\n <li>The formulation is intended for transdermal delivery and systemic absorption is the intended outcome<\/li>\n <li>Researchers need to understand the effect of penetration enhancers or other excipients on skin transport<\/li>\n <li>Regulatory guidance explicitly requires permeation data as part of a submission package<\/li>\n <li>The development program aims to correlate in vitro results with in vivo skin absorption data<\/li>\n<\/ol>\n<p>The use of excised human skin in IVPT studies is considered the gold standard for biological relevance, though animal skin models are used when human tissue is not available, with the understanding that permeability values may differ.<\/p>\n<h2>What regulatory frameworks govern the choice between IVRT and IVPT?<\/h2>\n<p>The choice between IVRT and IVPT is shaped by guidance from major regulatory bodies, primarily the FDA and EMA, as well as general frameworks such as GMP and GLP that govern how testing is conducted and documented.<\/p>\n<p>The FDA has issued product-specific guidance documents for certain topical formulations that specify whether IVRT, IVPT, or both are required as part of a bioequivalence demonstration. The FDA&#8217;s 2023 guidance on topical drug products reinforced IVPT as an acceptable method for demonstrating bioequivalence for select semi-solid formulations, provided the study design meets defined criteria for skin source, receptor fluid, and sampling protocol.<\/p>\n<p>The EMA similarly recognizes both methods within its guidance on quality and bioequivalence for topical products, with the method choice depending on the product type, the regulatory pathway, and the scientific justification provided by the applicant.<\/p>\n<p>In all cases, studies must be conducted under GLP conditions when the data will support regulatory submissions, and documentation must meet the traceability standards expected under GMP and, where applicable, 21 CFR Part 11 for electronic records. Researchers working in the Benelux region should also account for national competent authority expectations, which generally align with EMA guidance but may include specific procedural requirements.<\/p>\n<h2>Can IVRT and IVPT be used together in the same development program?<\/h2>\n<p>Yes, IVRT and IVPT are frequently used together within the same development program, and doing so provides a more complete picture of formulation performance than either method alone. Using both methods in sequence allows researchers to first optimize the formulation using the efficiency and reproducibility of IVRT, then confirm skin permeation behavior with IVPT at a later stage.<\/p>\n<p>A common workflow in semi-solid formulation development looks like this: IVRT is used during early screening to rank formulations by release rate and to identify candidates worth advancing. Once a shortlist of promising formulations is established, IVPT is applied to evaluate how those candidates perform in the context of skin transport. This staged approach conserves resources while still generating the biological data needed for regulatory and scientific purposes.<\/p>\n<p>Combining the two methods also supports mechanistic understanding. If a formulation shows high release in IVRT but low permeation in IVPT, this suggests that skin barrier properties, rather than formulation release, are the limiting factor. This kind of insight directly informs decisions about whether penetration enhancement strategies are needed.<\/p>\n<h2>What are the practical limitations of each method in a lab setting?<\/h2>\n<p>Both IVRT and IVPT have practical constraints that affect how they are implemented in laboratory workflows, and understanding these limitations helps in planning studies that are both scientifically sound and operationally feasible.<\/p>\n<h3>Limitations of IVRT<\/h3>\n<p>IVRT is technically straightforward and reproducible, but its main limitation is interpretive scope. Because it uses an inert membrane, IVRT data cannot be extrapolated to predict skin absorption or clinical performance. Regulatory reviewers are aware of this boundary, and IVRT data alone will not satisfy requirements where biological permeation evidence is expected. Additionally, selecting the right synthetic membrane and acceptor medium requires careful validation to ensure the method is discriminatory for the specific formulation type.<\/p>\n<h3>Limitations of IVPT<\/h3>\n<p>IVPT introduces biological variability that is inherent to working with skin tissue. Excised human skin is the preferred substrate, but its availability is limited, storage conditions are critical, and variability between donors can affect reproducibility. Animal skin models reduce the supply challenge but introduce uncertainty about how well the data translates to human biology. IVPT studies also require more complex experimental infrastructure, including controlled humidity and temperature environments, careful receptor fluid management, and rigorous tissue handling protocols to preserve barrier integrity throughout the experiment.<\/p>\n<h2>How ChemSPX supports IVRT and IVPT workflows in the Benelux<\/h2>\n<p>For formulation research laboratories across the Benelux region, selecting and implementing the right diffusion testing setup is as important as choosing the right method. ChemSPX works with research teams at universities, pharmaceutical companies, and contract research organizations to advise on instrumentation for in vitro release and permeation testing, including Franz diffusion cell systems and related laboratory equipment.<\/p>\n<p>ChemSPX&#8217;s support for IVRT and IVPT workflows includes:<\/p>\n<ul>\n <li>Expert advice on instrument selection based on your specific formulation type and regulatory requirements<\/li>\n <li>Installation and qualification (IQ\/OQ) of diffusion testing equipment in line with GMP and GLP standards<\/li>\n <li>Application-level support from product specialists who understand the demands of semi-solid formulation research<\/li>\n <li>Ongoing service and calibration to keep instruments performing reliably across long development programs<\/li>\n<\/ul>\n<p>Whether you are setting up a new IVRT or IVPT capability or looking to optimize an existing workflow, the ChemSPX team is available to help. <a href=\"https:\/\/chemspx.com\/nl\/contact\/\">Contact ChemSPX<\/a> to discuss your laboratory&#8217;s specific needs and find the right instrumentation solution for your formulation development program.<\/p>\n<div class=\"wp-block-seoaic-faq-block\">\n    <h2 class=\"seoaic-faq-section-title\">Veelgestelde vragen<\/h2>\n            <div class=\"seoaic-faq-item\">\n            <h3 class=\"seoaic-question\">\n                How do I validate that my IVRT method is discriminatory enough to detect meaningful formulation differences?            <\/h3>\n            <p class=\"seoaic-answer\">\n                A discriminatory IVRT method should be sensitive enough to detect intentional changes in formulation composition, such as variations in drug concentration, polymer grade, or excipient ratios. Validation typically involves preparing a set of formulations with known differences and confirming that the method produces statistically distinct release profiles for each. The FDA&#8217;s scale-up and post-approval changes (SUPAC) guidance and relevant product-specific guidances provide useful benchmarks for what level of discrimination is expected. If your method cannot distinguish between formulations that are known to differ, revisit your membrane selection, acceptor medium composition, and sampling intervals before proceeding.            <\/p>\n        <\/div>\n                <div class=\"seoaic-faq-item\">\n            <h3 class=\"seoaic-question\">\n                What are the most common mistakes researchers make when setting up a Franz diffusion cell experiment for the first time?            <\/h3>\n            <p class=\"seoaic-answer\">\n                The most frequent errors include inadequate temperature control, improper membrane hydration, air bubbles trapped in the receptor compartment, and inconsistent application of the formulation to the donor cell. Each of these can introduce variability that obscures real differences between formulations. For IVPT specifically, failing to verify skin barrier integrity before the experiment \u2014 using transepidermal water loss (TEWL) measurement or electrical resistance \u2014 is a critical oversight that can render the entire dataset unusable. Building a detailed standard operating procedure and running pilot experiments before committing to a full study design will catch most of these issues early.            <\/p>\n        <\/div>\n                <div class=\"seoaic-faq-item\">\n            <h3 class=\"seoaic-question\">\n                Which type of skin model is most appropriate for IVPT when excised human skin is not available?            <\/h3>\n            <p class=\"seoaic-answer\">\n                Porcine ear skin is the most widely accepted alternative to excised human skin due to its structural and lipid composition similarities to human skin, and it is readily available from abattoirs. However, porcine skin generally exhibits higher permeability than human skin, so quantitative values should not be directly extrapolated to human outcomes without appropriate correction factors or comparative data. Reconstructed human epidermis (RHE) models are another option and offer ethical and supply advantages, but they are currently best suited for irritation screening rather than quantitative permeation studies, as their barrier properties do not yet fully replicate native human skin.            <\/p>\n        <\/div>\n                <div class=\"seoaic-faq-item\">\n            <h3 class=\"seoaic-question\">\n                How should I choose the right acceptor fluid composition for my IVRT or IVPT study?            <\/h3>\n            <p class=\"seoaic-answer\">\n                The acceptor fluid must maintain sink conditions throughout the experiment, meaning the drug concentration in the receptor compartment should remain well below its saturation solubility \u2014 typically less than 10\u201330% of saturation \u2014 to ensure that release or permeation is not artificially limited by poor drug solubility in the medium. Phosphate buffered saline (PBS) at pH 7.4 is a common starting point for many topical formulations, but poorly soluble drugs may require the addition of a co-solvent or surfactant such as polyethylene glycol or bovine serum albumin. Always verify that any solubilizing agent used does not compromise membrane integrity, particularly in IVPT studies where skin barrier function must be preserved.            <\/p>\n        <\/div>\n                <div class=\"seoaic-faq-item\">\n            <h3 class=\"seoaic-question\">\n                At what stage of development should a formulation team first consider bringing in IVPT data for a regulatory submission?            <\/h3>\n            <p class=\"seoaic-answer\">\n                IVPT data should be planned for as soon as the regulatory pathway is defined and a reference product has been identified, particularly if bioequivalence demonstration is part of the submission strategy. Waiting until late-stage development to generate IVPT data is a common and costly mistake, as study failures or unexpected results leave little time for reformulation. Ideally, IVPT studies should be initiated once IVRT screening has identified a shortlisted formulation candidate, allowing the two datasets to be developed in parallel with the broader dossier. Consulting the relevant FDA product-specific guidance or EMA scientific advice early in the program will clarify exactly what IVPT study design elements \u2014 skin source, receptor fluid, sampling schedule \u2014 will be expected.            <\/p>\n        <\/div>\n                <div class=\"seoaic-faq-item\">\n            <h3 class=\"seoaic-question\">\n                Can IVRT data be used to support a post-approval manufacturing change without repeating clinical studies?            <\/h3>\n            <p class=\"seoaic-answer\">\n                Yes, this is one of the most practically valuable applications of IVRT. Regulatory frameworks such as the FDA&#8217;s SUPAC-SS guidance for semi-solid dosage forms allow manufacturers to use IVRT data to justify certain post-approval changes \u2014 including changes to manufacturing equipment, process parameters, or some excipient levels \u2014 without requiring new clinical or in vivo bioequivalence studies. The key requirement is that the IVRT method must have been validated as discriminatory and must have been established using the approved reference formulation. If your IVRT method was not set up with this use case in mind from the start, it may require additional validation work before it can support a regulatory change notification.            <\/p>\n        <\/div>\n                <div class=\"seoaic-faq-item\">\n            <h3 class=\"seoaic-question\">\n                How much biological variability should I expect in IVPT data, and how can I minimize it without compromising scientific integrity?            <\/h3>\n            <p class=\"seoaic-answer\">\n                Donor-to-donor variability is an inherent feature of IVPT studies using excised human skin, and coefficients of variation (CV) of 30\u201350% across donors are not uncommon, even in well-controlled experiments. This variability reflects real biological differences in skin barrier function between individuals and should not be artificially suppressed. To manage it appropriately, use a sufficient number of donor replicates \u2014 typically a minimum of three donors with multiple replicates per donor \u2014 and screen skin samples for barrier integrity before use. Normalizing data or using within-donor comparisons when evaluating formulation differences can also help isolate formulation effects from inter-donor noise without distorting the biological signal.            <\/p>\n        <\/div>\n        <\/div>","protected":false},"template":"","class_list":["post-8131","wiki_post","type-wiki_post","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>When should IVRT be used instead of IVPT in formulation development? | ChemSPX<\/title>\n<meta name=\"description\" content=\"Not sure whether to use IVRT or IVPT in your formulation program? Learn when each method applies, what regulators expect, and how to combine both for stronger results.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/chemspx.com\/nl\/wiki\/when-should-ivrt-be-used-instead-of-ivpt-in-formulation-development\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"When should IVRT be used instead of IVPT in formulation development? | ChemSPX\" \/>\n<meta property=\"og:description\" content=\"Not sure whether to use IVRT or IVPT in your formulation program? Learn when each method applies, what regulators expect, and how to combine both for stronger results.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/chemspx.com\/nl\/wiki\/when-should-ivrt-be-used-instead-of-ivpt-in-formulation-development\/\" \/>\n<meta property=\"og:site_name\" content=\"ChemSPX\" \/>\n<meta property=\"og:image\" content=\"https:\/\/chemspx.com\/wp-content\/uploads\/2026\/10\/pharmaceutical-researcher-membrane-diffusion-cell-lab.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschatte leestijd\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/chemspx.com\\\/nl\\\/wiki\\\/when-should-ivrt-be-used-instead-of-ivpt-in-formulation-development\\\/\",\"url\":\"https:\\\/\\\/chemspx.com\\\/nl\\\/wiki\\\/when-should-ivrt-be-used-instead-of-ivpt-in-formulation-development\\\/\",\"name\":\"When should IVRT be used instead of IVPT in formulation development? | ChemSPX\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/chemspx.com\\\/nl\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/chemspx.com\\\/nl\\\/wiki\\\/when-should-ivrt-be-used-instead-of-ivpt-in-formulation-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/chemspx.com\\\/nl\\\/wiki\\\/when-should-ivrt-be-used-instead-of-ivpt-in-formulation-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/chemspx.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/pharmaceutical-researcher-membrane-diffusion-cell-lab.webp\",\"datePublished\":\"2026-10-22T06:00:00+00:00\",\"description\":\"Not sure whether to use IVRT or IVPT in your formulation program? Learn when each method applies, what regulators expect, and how to combine both for stronger results.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/chemspx.com\\\/nl\\\/wiki\\\/when-should-ivrt-be-used-instead-of-ivpt-in-formulation-development\\\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/chemspx.com\\\/nl\\\/wiki\\\/when-should-ivrt-be-used-instead-of-ivpt-in-formulation-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/chemspx.com\\\/nl\\\/wiki\\\/when-should-ivrt-be-used-instead-of-ivpt-in-formulation-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/chemspx.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/pharmaceutical-researcher-membrane-diffusion-cell-lab.webp\",\"contentUrl\":\"https:\\\/\\\/chemspx.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/pharmaceutical-researcher-membrane-diffusion-cell-lab.webp\",\"width\":1024,\"height\":768,\"caption\":\"Pharmaceutical researcher placing a membrane diffusion cell on a lab bench, with glass vials of cream formulations and steel analytical equipment nearby.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/chemspx.com\\\/nl\\\/wiki\\\/when-should-ivrt-be-used-instead-of-ivpt-in-formulation-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/chemspx.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Wiki post\",\"item\":\"https:\\\/\\\/chemspx.com\\\/Wiki\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"When should IVRT be used instead of IVPT in formulation development?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/chemspx.com\\\/nl\\\/#website\",\"url\":\"https:\\\/\\\/chemspx.com\\\/nl\\\/\",\"name\":\"ChemSPX\",\"description\":\"ChemSPX\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/chemspx.com\\\/nl\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"When should IVRT be used instead of IVPT in formulation development? | ChemSPX","description":"Not sure whether to use IVRT or IVPT in your formulation program? Learn when each method applies, what regulators expect, and how to combine both for stronger results.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/chemspx.com\/nl\/wiki\/when-should-ivrt-be-used-instead-of-ivpt-in-formulation-development\/","og_locale":"nl_NL","og_type":"article","og_title":"When should IVRT be used instead of IVPT in formulation development? | ChemSPX","og_description":"Not sure whether to use IVRT or IVPT in your formulation program? Learn when each method applies, what regulators expect, and how to combine both for stronger results.","og_url":"https:\/\/chemspx.com\/nl\/wiki\/when-should-ivrt-be-used-instead-of-ivpt-in-formulation-development\/","og_site_name":"ChemSPX","og_image":[{"width":1024,"height":768,"url":"https:\/\/chemspx.com\/wp-content\/uploads\/2026\/10\/pharmaceutical-researcher-membrane-diffusion-cell-lab.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_misc":{"Geschatte leestijd":"11 minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/chemspx.com\/nl\/wiki\/when-should-ivrt-be-used-instead-of-ivpt-in-formulation-development\/","url":"https:\/\/chemspx.com\/nl\/wiki\/when-should-ivrt-be-used-instead-of-ivpt-in-formulation-development\/","name":"When should IVRT be used instead of IVPT in formulation development? | ChemSPX","isPartOf":{"@id":"https:\/\/chemspx.com\/nl\/#website"},"primaryImageOfPage":{"@id":"https:\/\/chemspx.com\/nl\/wiki\/when-should-ivrt-be-used-instead-of-ivpt-in-formulation-development\/#primaryimage"},"image":{"@id":"https:\/\/chemspx.com\/nl\/wiki\/when-should-ivrt-be-used-instead-of-ivpt-in-formulation-development\/#primaryimage"},"thumbnailUrl":"https:\/\/chemspx.com\/wp-content\/uploads\/2026\/10\/pharmaceutical-researcher-membrane-diffusion-cell-lab.webp","datePublished":"2026-10-22T06:00:00+00:00","description":"Not sure whether to use IVRT or IVPT in your formulation program? Learn when each method applies, what regulators expect, and how to combine both for stronger results.","breadcrumb":{"@id":"https:\/\/chemspx.com\/nl\/wiki\/when-should-ivrt-be-used-instead-of-ivpt-in-formulation-development\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/chemspx.com\/nl\/wiki\/when-should-ivrt-be-used-instead-of-ivpt-in-formulation-development\/"]}]},{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/chemspx.com\/nl\/wiki\/when-should-ivrt-be-used-instead-of-ivpt-in-formulation-development\/#primaryimage","url":"https:\/\/chemspx.com\/wp-content\/uploads\/2026\/10\/pharmaceutical-researcher-membrane-diffusion-cell-lab.webp","contentUrl":"https:\/\/chemspx.com\/wp-content\/uploads\/2026\/10\/pharmaceutical-researcher-membrane-diffusion-cell-lab.webp","width":1024,"height":768,"caption":"Pharmaceutical researcher placing a membrane diffusion cell on a lab bench, with glass vials of cream formulations and steel analytical equipment nearby."},{"@type":"BreadcrumbList","@id":"https:\/\/chemspx.com\/nl\/wiki\/when-should-ivrt-be-used-instead-of-ivpt-in-formulation-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/chemspx.com\/"},{"@type":"ListItem","position":2,"name":"Wiki post","item":"https:\/\/chemspx.com\/Wiki\/"},{"@type":"ListItem","position":3,"name":"When should IVRT be used instead of IVPT in formulation development?"}]},{"@type":"WebSite","@id":"https:\/\/chemspx.com\/nl\/#website","url":"https:\/\/chemspx.com\/nl\/","name":"ChemSPX","description":"ChemSPX","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/chemspx.com\/nl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"}]}},"_links":{"self":[{"href":"https:\/\/chemspx.com\/nl\/wp-json\/wp\/v2\/wiki_post\/8131","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/chemspx.com\/nl\/wp-json\/wp\/v2\/wiki_post"}],"about":[{"href":"https:\/\/chemspx.com\/nl\/wp-json\/wp\/v2\/types\/wiki_post"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/chemspx.com\/nl\/wp-json\/wp\/v2\/media\/8176"}],"wp:attachment":[{"href":"https:\/\/chemspx.com\/nl\/wp-json\/wp\/v2\/media?parent=8131"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}